Monday, November 14, 2016
- 9:00AM-11:00AM
-
Abstract Number: 1281
Feasibility and Reliability of the Spondyloarthritis Research Consortium of Canada Sacroiliac Joint Inflammation Score for Children with Spondyloarthritis
Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI- 9:00AM-11:00AM
-
Abstract Number: 1282
Feasibility and Reliability of the Spondyloarthritis Research Consortium of Canada Sacroiliac Joint Structural Score for Children with Spondyloarthritis
Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI- 9:00AM-11:00AM
-
Abstract Number: 1369
Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome- 9:00AM-11:00AM
-
Abstract Number: 1258
Female Gender Is Associated with a Poorer Response to TNF-Inhibitors in Ankylosing Spondylitis
Healthcare Disparities in Rheumatology - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1849
Fibroblast Growth Factor 9/ Fibroblast Growth Factor Receptor 3 Signaling Is Upstream of Several Profibrotic Pathways and Induces Fibroblast Activation and Tissue Fibrosis in SSc
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1870
First Pilot Study of an Implantable Loop Recorder (ILR) in Systemic Sclerosis Detects Significant Cardiac Arrhythmias with CMR Abnormalities
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1594
First-in-Human Pharmacokinetics and Safety of Escalating Single- and Multiple-Doses of GS-9876, a Novel, Oral SYK Inhibitor, in Healthy Subjects
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1504
Fluoroquinolone Resistance in Escherichia coli Urinary Tract Infections Among Patients with Rheumatoid Arthritis: Does Use of Hydroxichloroquine Matter?
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications- 9:00AM-11:00AM
-
Abstract Number: 1795
Four Years Follow-up of Subclinical Atherosclerosis in Systemic Lupus Erythematosus Patients
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life- 9:00AM-11:00AM
-
Abstract Number: 1541
Frailty Is Associated with Decreased Physical Function in Adults with Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications- 9:00AM-11:00AM
-
Abstract Number: 1513
FRAX Fracture Risk in Rheumatoid Arthritis – Assessments with and without Bone Mineral Density May Lead to Very Different Results in Individual Patients
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications- 9:00AM-11:00AM
-
Abstract Number: 1808
Frequency and Factors Associated with Thirty Day Hospital Readmissions Among Systemic Lupus Erythematosus Patients in a Community Hospital in the California Central Valley
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life- 9:00AM-11:00AM
-
Abstract Number: 1815
Frequency and Predictors of Attaining the Lupus Low Disease Activity State (LLDAS) in a Multinational SLE Cohort from the Asia Pacific
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life- 9:00AM-11:00AM
-
Abstract Number: 1385
Frequency of the Systemic Lupus Collaborating Clinics- Damage Index Items in Three Registries of Childhood-Onset Systemic Lupus Erythematosus
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome- 9:00AM-11:00AM
-
Abstract Number: 1859
Fucosyltransferase-1 Mediated Fucosylation of TGF-βR1 Is Critical to TGF-β Signaling in Scleroderma and in Bleomycin-Induced Fibrosis